Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer

• Published in: Scientific reports Vol. 14; no. 1; pp. 32147 - 12
• Main Authors: Guan, Yaping, Cui, Yu, Gong, Yanhong, Liang, Xiuju, Han, Xinyue, Chen, Yingcui, Xie, Hong, Zhang, Yuekai, Wang, Baocheng, Ye, Xin, Wang, Jun
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 30.12.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67; 631/67/1059/2325; 631/67/2321; 692/4028; Adult; Advanced cancer; Aged; Aged, 80 and over; Atypical response; Cancer; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - immunology; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Dissociated response; Female; Humanities and Social Sciences; Humans; Immune checkpoint inhibitor; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Immunotherapy - methods; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - immunology; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Lung Neoplasms - therapy; Male; Medical prognosis; Middle Aged; multidisciplinary; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - mortality; Neoplasms - therapy; Non-small cell lung carcinoma; Patients; PD-1 protein; PD-L1 protein; Programmed cell death protein-1; Progression-Free Survival; Pseudoprogression; Retrospective Studies; Science; Science (multidisciplinary); Small cell lung carcinoma; Treatment Outcome; Advanced cancer; Atypical response; Dissociated response; Immune checkpoint inhibitor; Pseudoprogression; Programmed cell death protein-1

Immune-related dissociated response (DR) has been recently recognized and have become a subject of ongoing interest. The purpose of the present study was to evaluate the frequency, treatment outcome, and predictors of DR in cancer patients with immune checkpoint inhibitors. We retrospectively collec...